Abstract
Background: Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD) and is associated with worse outcomes and increased mortality. Evaluation of PH is recommended in lung transplant candidates, but there are currently no standardized screening approaches. Trials have identified therapies that are effective in this setting, providing another rationale to routinely screen patients with ILD for PH. Research Question: What screening strategies for identifying PH in patients with ILD are supported by expert consensus? Study Design and Methods: The study convened a panel of 16 pulmonologists with expertise in PH and ILD, and used a modified Delphi consensus process with three surveys to identify PH screening strategies. Survey 1 consisted primarily of open-ended questions. Surveys 2 and 3 were developed from responses to survey 1 and contained statements about PH screening that panelists rated from −5 (strongly disagree) to 5 (strongly agree). Results: Panelists reached consensus on several triggers for suspicion of PH including the following: symptoms, clinical signs, findings on chest CT scan or other imaging, abnormalities in pulse oximetry, elevations in brain natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-proBNP), and unexplained worsening in pulmonary function tests or 6-min walk distance. Echocardiography and BNP/NT-proBNP were identified as screening tools for PH. Right heart catheterization was deemed essential for confirming PH. Interpretation: Many patients with ILD may benefit from early evaluation of PH now that an approved therapy is available. Protocols to evaluate patients with ILD often overlap with evaluations for pulmonary hypertension-interstitial lung disease and can be used to assess the risk of PH. Because standardized approaches are lacking, this consensus statement is intended to aid physicians in the identification of patients with ILD and possible PH, and provide guidance for timely right heart catheterization.
Original language | English (US) |
---|---|
Pages (from-to) | 145-155 |
Number of pages | 11 |
Journal | CHEST |
Volume | 162 |
Issue number | 1 |
DOIs | |
State | Published - Jul 2022 |
Keywords
- echocardiography
- idiopathic pulmonary fibrosis
- interstitial lung disease
- pulmonary hypertension
- right heart catheterization
- screening
- Hypertension, Pulmonary/diagnosis
- Delphi Technique
- Echocardiography
- Respiratory Function Tests/adverse effects
- Lung Diseases, Interstitial/complications
- Humans
ASJC Scopus subject areas
- Critical Care and Intensive Care Medicine
- Cardiology and Cardiovascular Medicine
- Pulmonary and Respiratory Medicine
Fingerprint
Dive into the research topics of 'Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: CHEST, Vol. 162, No. 1, 07.2022, p. 145-155.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease
T2 - A Multidisciplinary Delphi Study
AU - Rahaghi, Franck F.
AU - Kolaitis, Nicholas A.
AU - Adegunsoye, Ayodeji
AU - de Andrade, Joao A.
AU - Flaherty, Kevin R.
AU - Lancaster, Lisa H.
AU - Lee, Joyce S.
AU - Levine, Deborah J.
AU - Preston, Ioana R.
AU - Safdar, Zeenat
AU - Saggar, Rajan
AU - Sahay, Sandeep
AU - Scholand, Mary Beth
AU - Shlobin, Oksana A.
AU - Zisman, David A.
AU - Nathan, Steven D.
N1 - Funding Information: Author contributions: All authors agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. S. D. N. N. A. K. and F. F. R. made substantial contributions to the conception and design of the work. All authors contributed to the acquisition of the study data and participated in at least two surveys including the final survey. All authors contributed to the interpretation of the data, and to drafting and revising of the manuscript. All authors have read and approved the manuscript. Funding/support: This study was funded by an independent grant provided by United Therapeutics Corp. Financial/nonfinancial disclosures: The authors have reported to CHEST the following: F. F. R. has received writing support for the present manuscript from United Therapeutics; grants or contracts from Bayer, Janssen PH, and Acceleron; consulting fees from United Therapeutics, Janssen PH, Bayer, and Acceleron; and payments or honoraria from United Therapeutics, Janssen PH, and Bayer. N. A. K. has received consulting fees from United Therapeutics (outside the scope of this article) and advisory board fees from Bayer. A. A. has received consulting fees from Boehringer Ingelheim and Genentech, and payment or honoraria for serving on a speakers bureau for Boehringer Ingelheim. J. A. has received payments for lectures, manuscript writing, or educational events from Boehringer Ingelheim and Genentech, and for serving on a data and safety monitoring board (DSMB) for the NIH/NHLBI (Pulmonary Trials Consortium). K. R. F. has received consulting fees from Bellerophon, Respivant, Blade Therapeutics, Shionogi, DevPro, AstraZeneca, Pure Health, Horizon, FibroGen, Sun Pharmaceuticals, Pliant, United Therapeutics, Arrowhead, Lupin, Polarean, and PureTech; and chairs the steering committee for the Pulmonary Fibrosis Foundation patient registry. L. L. has received grants or contracts from Genentech, Boehringer Ingelheim, Respivant, Biogen, Celgene, Galapagos, Galactic, Novartis, Bristol Myers Squibb, and Bellerophon as a principal investigator for research through Vanderbilt University; has received consulting fees from AstraZeneca, Galapagos, and United Therapeutics; has served on speakers bureaus for Boehringer Ingelheim and Genentech; has participated on a DSMB for Senhwa; and is a member of the Pulmonary Fibrosis Foundation Registry Steering Committee and the CHEST Diffuse Ling Disease Committee. J. S. L. has received an NIH/NHLBI grant outside the submitted work; has received a grant from Boehringer Ingelheim (outside the submitted work); has received consulting fees from Galapagos, Boehringer Ingelheim, United Therapeutics, and Eleven P15, outside the submitted work; has participated on a DSMB for the TETON trial (United Therapeutics) and the DSMB for Avalyn; and is a senior medical advisor for the Pulmonary Fibrosis Foundation. I. R. P. has received medical writing support from Parexel in support for this article; has received grants from Acceleron, Actelion, PhaseBio, Tenax, and United Therapeutics; has received payments or honoraria from MedOnTheGo, Medscape, and Integrity CME; has received payment for expert testimony from Bayer; has participated on DSMBs for Acceleron, Actelion, Altavant, Respira, Pfizer, and United Therapeutics; and has a leadership role in the ISHLT. Z. S. has received medical writing support from United Therapeutics for other manuscripts; has received support for travel or meetings; has received consulting fees; and is on the advisory board from United Therapeutics, Johnson & Johnson, Bayer, Genentech, Boehringer Ingelheim, and United Therapeutics. S. S. has received an ACCP CHEST ILD research grant (2020); has received consulting fees from Bayer, J&J, United Therapeutics, and Acceleron; has received payments or honoraria from J&J, United Therapeutics, and Bayer; has received a patent submitted for J&J as an inventor (secondary titration of Uptravi); has participated on the DSMB for a clinical trial sponsored by the NIH and Biogen of dimethyl fumarate in scleroderma; has participated in advisory boards for United Therapeutics, Bayer, Liquidia, and Acceleron; and is a member in the PVD network and ACCP CHEST. M. B. S. received medical writing support from United Therapeutics for the present manuscript; has received consulting fees from United Therapeutics and Veracyte; has received payments or honoraria from United Therapeutics, Genentech, Boehringer Ingelheim, and Veracyte; has received support for travel or meetings form United Therapeutics; and has participated on a DSMB or advisory board for Veracyte, United Therapeutics, and Polarean. O. S. has received payment or honoraria from United Therapeutics, Bayer, and Johnson & Johnson; and has participated on DSMBs or advisory boards for United Therapeutics, Bayer, Johnson & Johnson, and Altavant. S. D. N. has received support for the present manuscript from United Therapeutics; has received consulting fees from United Therapeutics, Bellerophon, Merck, Bayer, Roche, and Boehringer Ingelheim; and has received payment for expert testimony from Roche. None declared (D. L. R. S. D. A. Z.). Role of sponsors: The sponsor had no role in the design of the study, the collection and analysis of the data, or the preparation of the manuscript. Other contributions: Editorial and logistic assistance was provided by Parexel International Corp. Medical writing support was provided by Edward K. Baldwin, PhD. Both were funded by an independent grant from United Therapeutics Corp. Additional information: The e-Figures and e-Table are available online under “Supplementary Data.” Funding Information: Funding/support: This study was funded by an independent grant provided by United Therapeutics Corp. Funding Information: Financial/nonfinancial disclosures: The authors have reported to CHEST the following: F. F. R. has received writing support for the present manuscript from United Therapeutics; grants or contracts from Bayer, Janssen PH, and Acceleron; consulting fees from United Therapeutics, Janssen PH, Bayer, and Acceleron; and payments or honoraria from United Therapeutics, Janssen PH, and Bayer. N. A. K. has received consulting fees from United Therapeutics (outside the scope of this article) and advisory board fees from Bayer. A. A. has received consulting fees from Boehringer Ingelheim and Genentech, and payment or honoraria for serving on a speakers bureau for Boehringer Ingelheim. J. A. has received payments for lectures, manuscript writing, or educational events from Boehringer Ingelheim and Genentech, and for serving on a data and safety monitoring board (DSMB) for the NIH/NHLBI (Pulmonary Trials Consortium). K. R. F. has received consulting fees from Bellerophon, Respivant, Blade Therapeutics, Shionogi, DevPro, AstraZeneca, Pure Health, Horizon, FibroGen, Sun Pharmaceuticals, Pliant, United Therapeutics, Arrowhead, Lupin, Polarean, and PureTech; and chairs the steering committee for the Pulmonary Fibrosis Foundation patient registry. L. L. has received grants or contracts from Genentech, Boehringer Ingelheim, Respivant, Biogen, Celgene, Galapagos, Galactic, Novartis, Bristol Myers Squibb, and Bellerophon as a principal investigator for research through Vanderbilt University; has received consulting fees from AstraZeneca, Galapagos, and United Therapeutics; has served on speakers bureaus for Boehringer Ingelheim and Genentech; has participated on a DSMB for Senhwa; and is a member of the Pulmonary Fibrosis Foundation Registry Steering Committee and the CHEST Diffuse Ling Disease Committee. J. S. L. has received an NIH/NHLBI grant outside the submitted work; has received a grant from Boehringer Ingelheim (outside the submitted work); has received consulting fees from Galapagos, Boehringer Ingelheim, United Therapeutics, and Eleven P15, outside the submitted work; has participated on a DSMB for the TETON trial (United Therapeutics) and the DSMB for Avalyn; and is a senior medical advisor for the Pulmonary Fibrosis Foundation. I. R. P. has received medical writing support from Parexel in support for this article; has received grants from Acceleron, Actelion, PhaseBio, Tenax, and United Therapeutics; has received payments or honoraria from MedOnTheGo, Medscape, and Integrity CME; has received payment for expert testimony from Bayer; has participated on DSMBs for Acceleron, Actelion, Altavant, Respira, Pfizer, and United Therapeutics; and has a leadership role in the ISHLT. Z. S. has received medical writing support from United Therapeutics for other manuscripts; has received support for travel or meetings; has received consulting fees; and is on the advisory board from United Therapeutics, Johnson & Johnson, Bayer, Genentech, Boehringer Ingelheim, and United Therapeutics. S.S. has received an ACCP CHEST ILD research grant (2020); has received consulting fees from Bayer, J&J, United Therapeutics, and Acceleron; has received payments or honoraria from J&J, United Therapeutics, and Bayer; has received a patent submitted for J&J as an inventor (secondary titration of Uptravi); has participated on the DSMB for a clinical trial sponsored by the NIH and Biogen of dimethyl fumarate in scleroderma; has participated in advisory boards for United Therapeutics, Bayer, Liquidia, and Acceleron; and is a member in the PVD network and ACCP CHEST. M. B. S. received medical writing support from United Therapeutics for the present manuscript; has received consulting fees from United Therapeutics and Veracyte; has received payments or honoraria from United Therapeutics, Genentech, Boehringer Ingelheim, and Veracyte; has received support for travel or meetings form United Therapeutics; and has participated on a DSMB or advisory board for Veracyte, United Therapeutics, and Polarean. O. S. has received payment or honoraria from United Therapeutics, Bayer, and Johnson & Johnson; and has participated on DSMBs or advisory boards for United Therapeutics, Bayer, Johnson & Johnson, and Altavant. S. D. N. has received support for the present manuscript from United Therapeutics; has received consulting fees from United Therapeutics, Bellerophon, Merck, Bayer, Roche, and Boehringer Ingelheim; and has received payment for expert testimony from Roche. None declared (D. L., R. S., D. A. Z.). Publisher Copyright: © 2022 The Author(s)
PY - 2022/7
Y1 - 2022/7
N2 - Background: Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD) and is associated with worse outcomes and increased mortality. Evaluation of PH is recommended in lung transplant candidates, but there are currently no standardized screening approaches. Trials have identified therapies that are effective in this setting, providing another rationale to routinely screen patients with ILD for PH. Research Question: What screening strategies for identifying PH in patients with ILD are supported by expert consensus? Study Design and Methods: The study convened a panel of 16 pulmonologists with expertise in PH and ILD, and used a modified Delphi consensus process with three surveys to identify PH screening strategies. Survey 1 consisted primarily of open-ended questions. Surveys 2 and 3 were developed from responses to survey 1 and contained statements about PH screening that panelists rated from −5 (strongly disagree) to 5 (strongly agree). Results: Panelists reached consensus on several triggers for suspicion of PH including the following: symptoms, clinical signs, findings on chest CT scan or other imaging, abnormalities in pulse oximetry, elevations in brain natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-proBNP), and unexplained worsening in pulmonary function tests or 6-min walk distance. Echocardiography and BNP/NT-proBNP were identified as screening tools for PH. Right heart catheterization was deemed essential for confirming PH. Interpretation: Many patients with ILD may benefit from early evaluation of PH now that an approved therapy is available. Protocols to evaluate patients with ILD often overlap with evaluations for pulmonary hypertension-interstitial lung disease and can be used to assess the risk of PH. Because standardized approaches are lacking, this consensus statement is intended to aid physicians in the identification of patients with ILD and possible PH, and provide guidance for timely right heart catheterization.
AB - Background: Pulmonary hypertension (PH) is a common complication of interstitial lung disease (ILD) and is associated with worse outcomes and increased mortality. Evaluation of PH is recommended in lung transplant candidates, but there are currently no standardized screening approaches. Trials have identified therapies that are effective in this setting, providing another rationale to routinely screen patients with ILD for PH. Research Question: What screening strategies for identifying PH in patients with ILD are supported by expert consensus? Study Design and Methods: The study convened a panel of 16 pulmonologists with expertise in PH and ILD, and used a modified Delphi consensus process with three surveys to identify PH screening strategies. Survey 1 consisted primarily of open-ended questions. Surveys 2 and 3 were developed from responses to survey 1 and contained statements about PH screening that panelists rated from −5 (strongly disagree) to 5 (strongly agree). Results: Panelists reached consensus on several triggers for suspicion of PH including the following: symptoms, clinical signs, findings on chest CT scan or other imaging, abnormalities in pulse oximetry, elevations in brain natriuretic peptide (BNP) or N-terminal pro-brain natriuretic peptide (NT-proBNP), and unexplained worsening in pulmonary function tests or 6-min walk distance. Echocardiography and BNP/NT-proBNP were identified as screening tools for PH. Right heart catheterization was deemed essential for confirming PH. Interpretation: Many patients with ILD may benefit from early evaluation of PH now that an approved therapy is available. Protocols to evaluate patients with ILD often overlap with evaluations for pulmonary hypertension-interstitial lung disease and can be used to assess the risk of PH. Because standardized approaches are lacking, this consensus statement is intended to aid physicians in the identification of patients with ILD and possible PH, and provide guidance for timely right heart catheterization.
KW - echocardiography
KW - idiopathic pulmonary fibrosis
KW - interstitial lung disease
KW - pulmonary hypertension
KW - right heart catheterization
KW - screening
KW - Hypertension, Pulmonary/diagnosis
KW - Delphi Technique
KW - Echocardiography
KW - Respiratory Function Tests/adverse effects
KW - Lung Diseases, Interstitial/complications
KW - Humans
UR - http://www.scopus.com/inward/record.url?scp=85132230687&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85132230687&partnerID=8YFLogxK
U2 - 10.1016/j.chest.2022.02.012
DO - 10.1016/j.chest.2022.02.012
M3 - Article
C2 - 35176276
AN - SCOPUS:85132230687
SN - 0012-3692
VL - 162
SP - 145
EP - 155
JO - CHEST
JF - CHEST
IS - 1
ER -